Company Overview
Monopar Therapeutics is a clinical-stage biopharmaceutical company developing treatments for Wilson disease and advanced cancers.
Key Financial Figures
Revenue
Not disclosed in the provided report.
EPS (Net Loss per Share)
The Q4 2025 net loss was $0.61 per share, improving from a net loss of $2.23 per share in Q4 2024. The full-year 2025 net loss was $1.85 per share, compared to $4.11 per share in 2024.
Additional Financial Insights
Monopar held $140.4 million in cash, cash equivalents, and short-term investments at the end of 2025. In 2025, a public offering generated approximately $91.9 million. Current funding is projected to sustain the company’s operations through at least December 31, 2027.